We just released 8 new high priority funding opportunities where your company can make a difference in meeting the needs of cancer patients… Please see the solicitation and join our webinar on August 24th….
SEATTLE, Aug. 16, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.
The partnership creates an end-to-end solution for the development and production of hMSC and exosome therapeutics leveraging RoosterBio’s well-established cell and media products and process development services, coupled with AGC Biologics’ global cell and gene therapy manufacturing capabilities.
The Washington, D.C./Baltimore region continued to see a tightening in its life sciences real estate market.
In particular, the region saw a decrease in life sciences vacancy in the second quarter of 2022, dropping from 3.6 percent to 1.4 percent since last year, according to CBRE’s latest national life sciences report.
Image: THE RECENT DEAL FOR THE TWINBROOK OFFICE CENTER HIGHLIGHTS THE DEMAND FOR LIFE SCIENCES SPACE IN THE MARYLAND SUBURBS OF D.C.
PHOTO: BY NEWMARK
The fiscal year 2022 program is now closed. The fiscal year 2023 program will begin accepting applications as follows: Commerce will begin accepting Form B QMBC applications on 8/23/2022, and Form A Investor applications on 9/7/2022. Additional information is available under the “Apply” section.
BIITC provides an investor with a refundable State income tax credit for an eligible investment in a Qualified Maryland Biotechnology Company (QMBC). The program supports investment in seed and early stage biotech companies to promote and grow the biotech industry in Maryland.
Aug 15, 2022
- If authorized, Novavax’ vaccine would be the first protein-based COVID-19 booster for adults
- If authorized, the Novavax COVID-19 Vaccine, Adjuvanted could be used as a booster dose for adults aged 18 and older vaccinated with any other currently available COVID-19 vaccine
GAITHERSBURG, Md., Aug. 15, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.
Two new medical startups, focusing on addressing vision loss and catheter-associated urinary tract infections (UTIs), are on the horizon thanks to the $200,000 in grants the research teams received from the Johns Hopkins University’s Louis B. Thalheimer Fund for Translational Research.
14 researchers applied to the Thalheimer Fund, which was created to provide seed funding for proof-of-concept and validation studies of inventions coming out of Hopkins. The awards from the fund range from $25,000 to $100,000.
“We are excited to have received strong applications for disruptive technologies with commercialization potential that can have a future impact on human health and well-being,” Nicole Snell, associate director of ventures at Johns Hopkins Technology Ventures’ (JHTV) FastForward accelerator, which helps university-affiliated founders commercialize their technologies, said in a statement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
VISION 2030: From Excellence to Preeminence
This summer, the University System of Maryland unveiled a new 10-year strategic plan—Vision 2030: From Excellence to Preeminence. The plan reflects 18 months of in-depth analysis. It coalesces intense discussions among dozens of groups of people with a stake in Maryland’s public universities—people with different opinions on higher education’s main objectives and different ideas on how to achieve them.
But one theme emerged across all groups: That students must serve as our starting point. They must set our agenda. They must center our work.
WALTHAM, Mass. and DUBLIN, Aug. 15, 2022 /PRNewswire/ — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. Q32 has recently completed a biomarker-enabled Phase 1 study characterizing pharmacokinetics, pharmacodynamics and safety of ADX-914 that demonstrated pharmacological effect on T cells in healthy volunteers. Q32 expects to initiate a Phase 2 trial in atopic dermatitis later this year and is planning to initiate a Phase 2 trial in a second autoimmune disease next year.
The world hasn’t seen commercial supersonic travel in nearly 20 years since the Concorde was retired in 2003, but all that is about to change with the development of a new, environmentally friendly airliner.
Meet Overture – the world’s fastest airliner that was developed by Denver-based Boom Supersonic.
Image: https://nypost.com